Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 38
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (10)

clinicaltrialsPublishedShowing 1–24 of 24 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05896007	Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT	unknown	Phase 2	29	Ruijin HospitalOTHER	1	Sep 5, 2023	clinicaltrials
NCT04481815	Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	unknown	Phase 2	240	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Nov 8, 2022